$AMLX
Amylyx Pharmaceuticals, Inc. Stock $amlx

$amlx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023007609 Filed on March 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$71.43M	$21.89M	$22.23M
YoY Change			7700.0%
Cost Of Revenue	$5.283M	$2.821M	$2.993M
YoY Change
Gross Profit	$66.15M	$19.06M	$19.24M
YoY Change
Gross Profit Margin	92.6%	87.11%	86.54%
Selling, General & Admin	$44.01M	$40.84M	$127.1M
YoY Change	67.01%	173.74%	226.53%
% of Gross Profit	66.53%	214.25%	660.85%
Research & Development	$24.19M	$22.81M	$93.45M
YoY Change	12.71%	70.32%	112.19%
% of Gross Profit	36.57%	119.67%	485.78%
Depreciation & Amortization	$204.0K	$182.0K	$487.0K
YoY Change	482.86%	727.27%	836.54%
% of Gross Profit	0.31%	0.95%	2.53%
Operating Expenses	$68.20M	$63.66M	$220.6M
YoY Change	42.63%	124.82%	165.84%
Operating Profit	-$2.053M	-$44.59M	-$201.3M
YoY Change	-95.71%		143.49%
Interest Expense	$3.718M	$3.157M	$4.291M
YoY Change	2738.17%	10423.33%	11819.44%
% of Operating Profit
Other Income/Expense, Net	$3.456M	-$689.0K	$3.740M
YoY Change	2985.71%	1067.8%	-170.85%
Pretax Income	$1.403M	-$42.13M	-$197.6M
YoY Change	-102.94%	48.62%	124.72%
Income Tax	-$200.0K	$579.0K	$774.0K
% Of Pretax Income	-14.26%
Net Earnings	$1.573M	-$42.70M	-$198.4M
YoY Change	-103.29%	50.66%	125.6%
Net Earnings / Revenue	2.2%	-195.13%	-892.38%
Basic Earnings Per Share	$0.02		-$3.39
Diluted Earnings Per Share	$0.02	-$0.65	-$3.39
COMMON SHARES
Basic Shares Outstanding	66.72M	66.26M	58.50M
Diluted Shares Outstanding	70.86M		58.50M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$345.7M	$346.9M	$346.9M
YoY Change	35.45%	260.96%	260.96%
Cash & Equivalents	$114.6M	$62.53M	$62.53M
Short-Term Investments	$231.1M	$284.4M	$284.4M
Other Short-Term Assets	$12.75M	$10.11M	$10.11M
YoY Change	23.98%	14.49%	14.49%
Inventory	$13.08M	$9.769M	$9.769M
Prepaid Expenses
Receivables	$17.56M	$15.31M	$15.31M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$389.1M	$382.1M	$382.1M
YoY Change	46.54%	264.11%	264.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.559M	$2.611M	$8.135M
YoY Change	98.37%	450.84%	1616.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$466.0K	$466.0K	$1.185M
YoY Change	2.19%	146.56%	526.98%
Total Long-Term Assets	$18.91M	$9.320M	$9.320M
YoY Change	111.23%	1305.73%	1305.73%
TOTAL ASSETS
Total Short-Term Assets	$389.1M	$382.1M	$382.1M
Total Long-Term Assets	$18.91M	$9.320M	$9.320M
Total Assets	$408.0M	$391.5M	$391.5M
YoY Change	48.65%	270.64%	270.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.77M	$6.257M	$6.257M
YoY Change	7.22%	43.12%	43.12%
Accrued Expenses	$38.75M	$40.35M	$40.35M
YoY Change	119.43%	209.83%	209.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$51.62M	$46.61M	$46.61M
YoY Change	86.3%	167.93%	167.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.694M	$4.237M	$4.237M
YoY Change	-36.16%	12005.71%	12005.71%
Total Long-Term Liabilities	$3.694M	$4.237M	$4.237M
YoY Change	-36.16%	12005.71%	12005.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.62M	$46.61M	$46.61M
Total Long-Term Liabilities	$3.694M	$4.237M	$4.237M
Total Liabilities	$55.31M	$50.85M	$50.85M
YoY Change	65.14%	191.7%	191.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$352.6M	-$354.2M
YoY Change	73.12%	127.28%
Common Stock	$705.3M	$694.9M
YoY Change	58.56%	14786.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$352.6M	$340.6M	$340.6M
YoY Change
Total Liabilities & Shareholders Equity	$408.0M	$391.5M	$391.5M
YoY Change	48.65%	270.64%	270.64%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$1.573M	-$42.70M	-$198.4M
YoY Change	-103.29%	50.66%	125.6%
Depreciation, Depletion And Amortization	$204.0K	$182.0K	$487.0K
YoY Change	482.86%	727.27%	836.54%
Cash From Operating Activities	-$5.072M	-$49.70M	-$179.9M
YoY Change	-87.52%	75.96%	140.47%
INVESTING ACTIVITIES
Capital Expenditures	$250.0K	$620.0K	$2.526M
YoY Change	-26.9%	-433.33%	-815.58%
Acquisitions
YoY Change
Other Investing Activities	$56.24M	-$227.6M	-$236.5M
YoY Change	-156.83%	-7685.33%	413.46%
Cash From Investing Activities	$55.99M	-$228.2M	-$239.0M
YoY Change	-156.38%	-8208.74%	414.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.040M	232.2M	431.8M
YoY Change	-99.48%	-21899.25%	172.41%
NET CHANGE
Cash From Operating Activities	-5.072M	-49.70M	-179.9M
Cash From Investing Activities	55.99M	-228.2M	-239.0M
Cash From Financing Activities	1.040M	232.2M	431.8M
Net Change In Cash	52.04M	-45.72M	12.87M
YoY Change	-13.91%	72.54%	-65.51%
FREE CASH FLOW
Cash From Operating Activities	-$5.072M	-$49.70M	-$179.9M
Capital Expenditures	$250.0K	$620.0K	$2.526M
Free Cash Flow	-$5.322M	-$50.32M	-$182.4M
YoY Change	-87.01%	79.33%	145.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001658551
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41199
CY2022	dei	Entity Registrant Name EntityRegistrantName	Amylyx Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4600503
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	43 Thorndike St.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02141
CY2022	dei	City Area Code CityAreaCode	617
CY2022	dei	Local Phone Number LocalPhoneNumber	682-0917
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	AMLX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	788100000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	66716388
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche, LLC
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62526000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50191000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	284419000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	45927000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10113000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5392000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15306000
CY2022Q4	us-gaap	Inventory Net InventoryNet	9769000
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3441000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	382133000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	104951000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2611000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	474000
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	719000
CY2021Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	189000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5524000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	466000
CY2022Q4	us-gaap	Assets Assets	391453000
CY2021Q4	us-gaap	Assets Assets	105614000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6257000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4372000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	38312000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13024000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2040000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46609000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17396000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4237000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	35000
CY2022Q4	us-gaap	Liabilities Liabilities	50846000
CY2021Q4	us-gaap	Liabilities Liabilities	17431000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	56500000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66512011
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66512011
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7020487
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7020487
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	694906000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4667000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354220000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155845000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-86000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	340607000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-151168000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391453000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105614000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22230000
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	285000
CY2022	us-gaap	Revenues Revenues	22230000
CY2021	us-gaap	Revenues Revenues	285000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2993000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93450000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44040000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	127128000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38933000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	223571000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	82973000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-201341000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-82688000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	4291000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000
CY2021	amlx	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	5228000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-551000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3740000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5243000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-197601000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-87931000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	774000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198375000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-87931000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.39
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.39
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.35
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.35
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58495587
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58495587
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6586349
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6586349
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198375000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-87931000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-69000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-26000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-5000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-95000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-198470000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87922000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-66725000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	343000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3136000
CY2021	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax	9000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-87931000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-151168000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	239351000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	196379000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2189000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21714000
CY2022	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax	-95000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-198375000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	340607000
CY2022	us-gaap	Profit Loss ProfitLoss	-198375000
CY2021	us-gaap	Profit Loss ProfitLoss	-87931000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	21714000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3136000
CY2022	us-gaap	Depreciation Depreciation	487000
CY2021	us-gaap	Depreciation Depreciation	52000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2056000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-121000
CY2021	amlx	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	5228000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15306000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9769000
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-487000
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	144000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5221000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4486000
CY2022	amlx	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1635000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	456000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-125000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1854000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	670000
CY2022	amlx	Increase Decrease In Accrued Expenses And Deferred Rent IncreaseDecreaseInAccruedExpensesAndDeferredRent	26052000
CY2021	amlx	Increase Decrease In Accrued Expenses And Deferred Rent IncreaseDecreaseInAccruedExpensesAndDeferredRent	8432000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-917000
CY2021	amlx	Increase Decrease In Accrued Interests Dueto Related Parties IncreaseDecreaseInAccruedInterestsDuetoRelatedParties	-2000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-179871000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74799000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2526000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	353000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	415873000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	49053000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	179411000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3000000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-238988000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46406000
CY2021	amlx	Proceeds From Repayments Of Paycheck Protection Program Loan ProceedsFromRepaymentsOfPaycheckProtectionProgramLoan	-263000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	200897000
CY2022	amlx	Proceeds From Follow On Offering ProceedsFromFollowOnOffering	231550000
CY2022	amlx	Initial Public Offering Cost Paid InitialPublicOfferingCostPaid	2044000
CY2022	amlx	Follow On Offering Costs Paid FollowOnOfferingCostsPaid	803000
CY2021	amlx	Proceeds From Issuance Of Convertible Notes Related Parties ProceedsFromIssuanceOfConvertibleNotesRelatedParties	14272000
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	11887000
CY2021	amlx	Issuance Costs Related To Conversion Of Convertible Notes IssuanceCostsRelatedToConversionOfConvertibleNotes	50000
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	135000000
CY2021	amlx	Issuance Costs Related To Issuance Of Series Redeemable Convertible Preferred Stock IssuanceCostsRelatedToIssuanceOfSeriesRedeemableConvertiblePreferredStock	209000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2189000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	343000
CY2021	amlx	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	2474000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	431789000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	158506000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-65000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12865000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37314000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50380000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13066000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63245000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50380000
CY2021	amlx	Conversion Of Convertible Notes And Accrued Interest Into Redeemable Convertible Preferred Stock ConversionOfConvertibleNotesAndAccruedInterestIntoRedeemableConvertiblePreferredStock	32548000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	26000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5000
CY2022	amlx	Purchases Of Property And Equipment Included In Accounts Payable PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable	98000
CY2021	amlx	Purchases Of Property And Equipment Included In Accounts Payable PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable	22000
CY2021	amlx	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	967000
CY2022	amlx	Right Of Use Assets And Liabilities Upon Asc842 Adoption RightOfUseAssetsAndLiabilitiesUponAsc842Adoption	2201000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4958000
CY2022	amlx	Movement Of Deferred Offering Costs To Equity MovementOfDeferredOfferingCostsToEquity	5457000
CY2022	amlx	Follow On Offering Costs Included In Accounts Payable And Accrued Expenses FollowOnOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	136000
CY2022	amlx	Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering ConversionOfPreferredStockToCommonStockUponInitialPublicOffering	239351000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	27000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. Nature of Business</span><span style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Amylyx Pharmaceuticals, Inc., together with its wholly owned subsidiaries, known as Amylyx or the Company, is a commercial-stage biotechnology company with a mission to one day end the suffering caused by neurodegenerative diseases. The Company is focused on the development and potential global commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis, or ALS. Our first product, RELYVRIO® (sodium phenylbutyrate and taurursodiol), previously known as AMX0035 in the U.S., is approved in the U.S. for the treatment of ALS in adults. AMX0035 is also approved with conditions by Health Canada and marketed as ALBRIOZA for the treatment of ALS in Canada. The Company’s Marketing Authorisation Application, or MAA, for AMX0035 for the treatment of ALS remains under review by the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA. The Company is developing AMX0035 for other neurodegenerative diseases by leveraging its unique knowledge and relationships in the neurodegenerative space.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, the outcome of preclinical studies and clinical trials, market acceptance and the successful commercialization of ALBRIOZA, which received marketing authorization with conditions in Canada in June 2022, and RELYVRIO, which was approved by the FDA in the U.S. in September 2022, potential difficulties with or delays in timing with respect to the regulatory approval processes of the EMA and other comparable foreign authorities, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, ability to secure additional capital to fund operations, and risks associated with the economic challenges caused by the COVID-19 pandemic and economic uncertainty in various global markets caused by geopolitical instability and conflict. The Company and its contractors may experience disruptions in supply of items that are essential for its research and development and commercial activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada used in the manufacturing of AMX0035, and any future product candidates.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In accordance with Accounting Standards Update, or ASU, 2014-15,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its efforts to research and development and pre-commercialization activities, including recruiting management and technical staff, raising capital, producing materials for preclinical studies and clinical trials, and building infrastructure to support such activities. Expenses have primarily been for research and development and related general and administrative costs, and we anticipate that our selling, general and administrative expenses will continue to increase in the future as we further increase our headcount to support our continued research activities and development of AMX0035 and as we continue to increase headcount and incur other significant costs related to our commercialization activities. The Company has generated revenues through five grants from the ALS Association, ALS Finding a Cure Foundation, Cure Alzheimer’s Fund, Alzheimer’s Drug Discovery Foundation and Alzheimer’s Association, or Grantors. In addition to money received from its grants, the Company has also financed its operations through the public offering of its common stock, private sales of preferred stock, and convertible notes, and more recently through revenue from sales of RELYVRIO and ALBRIOZA in the U.S. and Canada, respectively. <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since inception. As of December 31, 2022, the Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">354.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. The Company expects its operating losses and negative operating cash flows may continue into the future as it continues initial sales of ALBRIOZA in Canada and RELYVRIO in the U.S., and continues to build capabilities and develop AMX0035, and any future product candidates. The Company expects that its cash, cash equivalents and short-term investments as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, and product revenue from RELYVRIO and ALBRIOZA sales, will enable the Company to fund its ongoing operating expenses and capital expenditure requirements for at least the twelve-month period following the issuance of these consolidated financial statements.</span></p>
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354200000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates—</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: Gross-to-net, or GTN, adjustments, inventory, determining the fair value of convertible notes, accrued expenses, stock-based compensation, operating lease right-of-use assets and lease liabilities, valuation allowance for deferred tax assets and research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	amlx	Incremental Costs Expenses IncrementalCostsExpenses	0
CY2021	amlx	Incremental Costs Expenses IncrementalCostsExpenses	0
CY2022	us-gaap	Proceeds From Grantors ProceedsFromGrantors	0
CY2021	us-gaap	Proceeds From Grantors ProceedsFromGrantors	300000
CY2022	amlx	Cash And Cash Equivalents Maturity Date Description CashAndCashEquivalentsMaturityDateDescription	The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents.
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	700000
CY2021Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000
CY2021	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	-0
CY2021	amlx	Gain Contingency Recorded Amount GainContingencyRecordedAmount	0
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk—</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable, net. The Company maintains its cash in financial institutions that it believes have high credit quality. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s accounts receivable, net at December 31, 2022, represents amounts due to the Company from customers. Amylyx performs ongoing credit evaluations of its customers and generally does not require collateral. The Company monitors its exposure and records a reserve against uncollectible amounts as necessary. </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> customers individually accounted for approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">97</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of total gross product revenue in 2022 and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> customers individually accounted for approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of total accounts receivable, net as of December 31, 2022.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Convertible Note—Derivative—</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company reviews the terms of the convertible note issued to determine whether there are features, including redemption and conversion features, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at the end of each reporting period and immediately prior to the conversion or the extinguishment of the convertible note. Changes in the fair value are reported in the consolidated statement of operations. When the convertible note contains embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those host instruments being recorded at a discount from their face value. The discount from the face value of the convertible note, together with the stated interest on the host instrument, is amortized over the life of the host instrument through periodic charges to interest expense. The Company’s convertible notes, as further discussed in Note 8, had embedded derivatives that required bifurcation from the host instrument.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Convertible Note—Beneficial Conversion Feature—</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">If the conversion feature is not treated as a derivative, the Company assesses whether it is a beneficial conversion feature, or BCF. A BCF exists if the conversion price of the convertible note is less than the price of the stock into which it is convertible to on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the effective conversion price and the fair value of the stock into which it is convertible to and is recorded as additional paid-in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the debt discount as non-cash interest expense over the life of the underlying convertible note using the effective interest method. If the convertible note is retired early, the associated debt discount is then recognized immediately as non-cash interest expense in the consolidated statements of operations. If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible note is treated as traditional debt.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022Q4	amlx	Deferred Offering Cost Net Of Equity Financing DeferredOfferingCostNetOfEquityFinancing	5500000
CY2021Q4	amlx	Deferred Offering Cost Net Of Equity Financing DeferredOfferingCostNetOfEquityFinancing	0
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3400000
CY2022	amlx	Gain Contingency Recorded Amount GainContingencyRecordedAmount	0
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	-0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	amlx	Sales And Marketing Costs Policy Policy Textblock SalesAndMarketingCostsPolicyPolicyTextblock	<p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Sales and Marketing Costs—</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Sales and marketing expenses consist primarily of wages and benefits for sales and marketing personnel, professional and consulting fees, administrative travel expenses, and marketing and advertising costs such as marketing literature, promotional activities, conferences and seminars and branding. Sales and marketing costs are expensed as incurred and included in selling, general and administrative expenses in the accompanying consolidated statements of operations.</span></p>
CY2022	amlx	Revenue From Contract With Customer Excluding Assessed Tax Gross RevenueFromContractWithCustomerExcludingAssessedTaxGross	27104000
CY2022	amlx	Gross To Net Adjustments GrossToNetAdjustments	-4874000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22230000
CY2022	amlx	Available For Sale Investments Contractual Maturity Period AvailableForSaleInvestmentsContractualMaturityPeriod	P1Y
CY2021	amlx	Available For Sale Investments Contractual Maturity Period AvailableForSaleInvestmentsContractualMaturityPeriod	P1Y
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0
CY2022	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0
CY2021	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7151000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1681000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	937000
CY2022Q4	us-gaap	Inventory Net InventoryNet	9769000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	22900000
CY2022Q4	amlx	Long Term Raw Materials Not Yet Realized LongTermRawMaterialsNotYetRealized	3200000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3151000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	527000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	540000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	53000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2611000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	474000
CY2022Q4	amlx	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	8424000
CY2021Q4	amlx	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	5666000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15231000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4280000
CY2022Q4	amlx	Accrued Manufacturing AccruedManufacturing	4596000
CY2022Q4	amlx	Accrued Consulting And Other Professional Fess AccruedConsultingAndOtherProfessionalFess	4116000
CY2021Q4	amlx	Accrued Consulting And Other Professional Fess AccruedConsultingAndOtherProfessionalFess	2820000
CY2022Q4	amlx	Rebates And Other Gross To Net Adjustments RebatesAndOtherGrossToNetAdjustments	3582000
CY2022Q4	amlx	Royalty Payable RoyaltyPayable	1358000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1005000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	258000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	38312000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13024000
CY2022	amlx	Transfer Of Levels Of Investment Securities Fair Value Assets Description TransferOfLevelsOfInvestmentSecuritiesFairValueAssetsDescription	The Company has not transferred any investment securities between the classification levels
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company entered into an office space lease at 121 First Street in Cambridge, Massachusetts on January 10, 2022, for 36 months, with an option to extend the lease for 3 years.
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P36M
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5000000.0
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5000000.0
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2136000
CY2022	us-gaap	Lease Cost LeaseCost	2136000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	56500000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5524000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2040000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4237000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6277000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1400000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2417000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2478000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1586000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	476000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6957000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	680000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6277000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022	amlx	Operating Lease Weighted Average Incremental Borrowing Rate OperatingLeaseWeightedAverageIncrementalBorrowingRate	0.073
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	532000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	541000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	555000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	563000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	476000
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2667000
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	37710624
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	37107459
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	37107459
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	239351000
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	416466000
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	39474330
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2022	amlx	Common Stock Number Of Voting Rights CommonStockNumberOfVotingRights	1
CY2022	us-gaap	Dividends Dividends	0
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0
CY2021	us-gaap	Dividends Dividends	0
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0
CY2022Q4	amlx	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	66512011
CY2021Q4	amlx	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	7020487
CY2022Q4	amlx	Common Stock Authorized And Reserved For Future Issuance CommonStockAuthorizedAndReservedForFutureIssuance	12038998
CY2021Q4	amlx	Common Stock Authorized And Reserved For Future Issuance CommonStockAuthorizedAndReservedForFutureIssuance	46257833
CY2022Q4	amlx	Unreserved Common Stock Available For Future Issuance UnreservedCommonStockAvailableForFutureIssuance	221448991
CY2021Q4	amlx	Unreserved Common Stock Available For Future Issuance UnreservedCommonStockAvailableForFutureIssuance	3221680
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	11369369
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	19.00
CY2022Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	196400000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7697812
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	32.00
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	230600
CY2022Q4	us-gaap	Share Price SharePrice	20.29
CY2021Q4	us-gaap	Share Price SharePrice	7.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0197
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0101
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y25D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M23D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8875
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8161
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5339011
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.54
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15627000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4237720
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.29
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	950013
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.33
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	145768
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.98
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8480950
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.19
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	201765000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2055416
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	63408000
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	6425534
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	15.47
CY2022	amlx	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm	P8Y7M6D
CY2022Q4	amlx	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue	138357000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14200000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6200000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8800000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1300000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21714000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3136000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21714000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3136000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-198704000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-87904000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1103000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-27000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-197601000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-87931000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	774000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	774000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.040
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.255
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.244
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.021
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	42673000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	24303000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	10628000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	5474000
CY2022Q4	amlx	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	18079000
CY2021Q4	amlx	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	6205000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	5721000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5581000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2808000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	9284000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1556000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	91966000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40346000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90587000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40346000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1379000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-1379000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1379000
CY2022	us-gaap	Tax Credit Carryforward Description TaxCreditCarryforwardDescription	The tax credit carryforwards will expire at various dates beginning in 2034.
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40346000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18900000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	50241000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21446000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90587000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40346000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	564000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	349000
CY2022Q4	amlx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-32000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	481000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	215000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1013000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	564000
CY2022	us-gaap	Significant Change In Unrecognized Tax Benefits Nature Of Event SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent	The Company does not expect the amount of unrecognized tax benefits to change over next 12 months.
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9221247
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44813341
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company entered into an office space lease at 121 First Street in Cambridge, Massachusetts on January 10, 2022, for 36 months, with an option to extend the lease for 3 years.
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P36M
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	700000
CY2021Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000

Files In Submission

Name	View Source	Status
amlx-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0000950170-23-007609-index-headers.html	Edgar Link	pending
0000950170-23-007609-index.html	Edgar Link	pending
0000950170-23-007609.txt	Edgar Link	pending
0000950170-23-007609-xbrl.zip	Edgar Link	pending
amlx-20221231.htm	Edgar Link	pending
amlx-20221231.xsd	Edgar Link	pending
amlx-ex10_18.htm	Edgar Link	pending
amlx-ex21_1.htm	Edgar Link	pending
amlx-ex23_1.htm	Edgar Link	pending
amlx-ex31_1.htm	Edgar Link	pending
amlx-ex31_2.htm	Edgar Link	pending
amlx-ex31_3.htm	Edgar Link	pending
amlx-ex32_1.htm	Edgar Link	pending
amlx-ex32_2.htm	Edgar Link	pending
amlx-ex32_3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img109617586_0.jpg	Edgar Link	pending
img109617586_1.jpg	Edgar Link	pending
img109617586_10.jpg	Edgar Link	pending
img109617586_11.jpg	Edgar Link	pending
img109617586_12.jpg	Edgar Link	pending
img109617586_2.jpg	Edgar Link	pending
img109617586_3.jpg	Edgar Link	pending
img109617586_4.jpg	Edgar Link	pending
img109617586_5.jpg	Edgar Link	pending
img109617586_6.jpg	Edgar Link	pending
img109617586_7.jpg	Edgar Link	pending
amlx-20221231_def.xml	Edgar Link	unprocessable
amlx-20221231_lab.xml	Edgar Link	unprocessable
amlx-20221231_htm.xml	Edgar Link	completed
amlx-20221231_pre.xml	Edgar Link	unprocessable
img109617586_8.jpg	Edgar Link	pending
img109617586_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMLX
Amylyx Pharmaceuticals, Inc. Stock $amlx

2023 Q1 Form 10-K Financial Statement

#000095017023007609 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMLX Amylyx Pharmaceuticals, Inc. Stock $amlx

2023 Q1 Form 10-K Financial Statement

#000095017023007609 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMLX
Amylyx Pharmaceuticals, Inc. Stock $amlx